Your session is about to expire
← Back to Search
Crizotinib for Lung Cancer
Study Summary
This trial will test the effectiveness of crizotinib in treating ROS1- or MET-mutated non-small cell lung cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 3 trial • 207 Patients • NCT01639001Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have no significant side effects from previous cancer treatments.I am 18 years old or older.I can take care of myself but might not be able to do heavy physical work.I haven't had chemotherapy, targeted therapy, or radiotherapy in the last 4 weeks.My blood, organs, and heart are healthy enough for treatment.You are expected to live for more than 12 weeks.My lung cancer is advanced, not squamous, and has specific genetic changes.I am taking medication that strongly affects liver enzyme CYP3A4.I have brain metastases that haven't been treated and are causing symptoms.I can take pills and don’t have major stomach or bowel issues affecting drug absorption.I can safely receive Crizotinib treatment.You have a disease that can be measured using specific guidelines.I have a long QT syndrome or my heart's electrical recovery time is 500 msec or longer.You are allergic to medications similar to crizotinib.
- Group 1: MET-amplification
- Group 2: ROS1 Rearrangement
- Group 3: MET-activating Mutation (exon 14)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has research been conducted with Crizotinib in the past?
"Currently, 32 Crizotinib trials are ongoing. Of these, 6 have entered the third phase of clinical research and they originate from a single site in Pahrump, Nevada. Globally, there are 6887 locations running studies related to this drug therapy."
What adverse effects should be expected with Crizotinib treatments?
"The safety of Crizotinib has been judged to be a 2 on the 1-3 scale, owing to its status as a Phase 2 trial. This implies that while there is data backing up the medication's safety, efficacy cannot yet be confirmed."
What is the maximum number of participants accepted for this research endeavor?
"Affirmative. The clinicaltrials.gov website states that this medical research is currently enlisting participants, with the first post being published on December 3rd 2019 and the most recent update occurring November 26th 2021. This trial requires 50 individuals to be recruited from a single site."
Is there an opportunity to join this experiment at the current time?
"According to official records from clinicaltrials.gov, this medical trial is presently recruiting participants. The study was first posted on December 3rd 2019 and its information was most recently updated on November 26th 2021."
Is this an unprecedented research endeavor?
"Since 2011, Crizotinib has been extensively studied. Pfizer was the initial sponsor of a clinical trial in 2011 involving 44 patients; it eventually led to Phase 1 drug approval. Currently, 32 trials are active worldwide across 1204 cities and 36 nations."
Share this study with friends
Copy Link
Messenger